Medical devices, healthcare technology and the business of care
PMA approval · P240001

PearlMatrix Bone Graft

Cerapedics, Inc. · Decision date Jun 18, 2025

FDA DECISIONP240001

What did the FDA approve?

FDA records P240001 as an original PMA application. The recorded decision is approval, dated Jun 18, 2025.

FDA approval order statement

PearlMatrix Bone Graft is indicated for intervertebral body fusion of the spine in skeletally mature patients. PearlMatrix Bone Graft is intended to be used in conjunction with a PEEK TLIF Fusion Device and supplemental internal spinal fixation systems cleared by the FDA for use in the lumbosacral spine. The system is to be used in patients who have had at least six months of non-operative treatment. PearlMatrix Bone Graft is intended for use at one level in the lumbar spine (L2-S1) for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back and/or radicular pain of discogenic origin with degeneration of the disc confirmed by history, physical exam, and radiographic studies.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Jun 18, 2025

FDA source record

Regulatory record facts

Identifier
P240001
Regulatory pathway
Premarket approval application
Product code
NOX
Decision code
APPR
Decision date
Jun 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Filler, bone void, synthetic peptide.

Product code
NOX
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240001 received

    Application receipt date recorded by FDA.

  2. P240001 · FDA decision

    APPR

  3. P240001/S003 · Related supplement

    PearlMatrixTM Peptide Enhanced Bone Graft

Timeline entries are records held by MedtechLedger for P240001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240001

Product / regulatory recordCompanyPathwayDecision dateSource
Cerapedics, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code NOX

Product / regulatory recordCompanyPathwayDecision dateSource
Cerapedics, LLCPMA supplementSep 16, 2026FDA
Cerapedics, LLCPMA approvalNov 3, 2015FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerapedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11025 Dover St., Suite 1600, Westminster, CO, 80021

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records